In an interview with PharmaShots, Mark Frohlich, CEO at Indapta Therapeutics shared his views on the closing of $50M A financing and how it will advance its cell therapy drug developmentShots:The company closes $50M A financing, co-led by RA Capital Management, LP, Vertex Ventures HC, and Bayer AG with Mark Frohlich appointed as M.D.,…
